|
ARL2BP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.68889999996713E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.14579999999742E-05 |
| Normal-vs-Stage2 |
1.130970E-01 |
| Normal-vs-Stage3 |
3.23899999998822E-06 |
| Normal-vs-Stage4 |
9.97879999964368E-07 |
| Stage1-vs-Stage2 |
5.572200E-02 |
| Stage1-vs-Stage3 |
4.273800E-01 |
| Stage1-vs-Stage4 |
1.894750E-01 |
| Stage2-vs-Stage3 |
3.833700E-02 |
| Stage2-vs-Stage4 |
1.512430E-02 |
| Stage3-vs-Stage4 |
5.572200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.69859999965949E-07 |
| Normal-vs-AfricanAmerican |
1.499140E-03 |
| Normal-vs-Asian |
2.583000E-03 |
| Caucasian-vs-AfricanAmerican |
8.825200E-01 |
| Caucasian-vs-Asian |
4.643600E-01 |
| AfricanAmerican-vs-Asian |
5.306600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.236240E-04 |
| Normal-vs-Female |
2.94150000001991E-06 |
| Male-vs-Female |
5.444000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.93349999997061E-06 |
| Normal-vs-Age(41-60Yrs) |
1.03230000003673E-06 |
| Normal-vs-Age(61-80Yrs) |
5.980500E-04 |
| Normal-vs-Age(81-100Yrs) |
9.702300E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.127200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.277600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.822000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.211400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.031600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.224400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.520400E-02 |
| Classical-VS-Follicular |
8.541000E-01 |
| Classical-VS-Other |
1.185790E-01 |
| Classical-VS-Normal |
1.360740E-04 |
| Tall-VS-Follicular |
1.065830E-01 |
| Tall-VS-Other |
5.427800E-01 |
| Tall-VS-Normal |
1.77231999999306E-05 |
| Follicular-VS-Other |
1.668760E-01 |
| Follicular-VS-Normal |
1.844850E-03 |
| Other-VS-Normal |
1.563910E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.8596999997238E-07 |
| Normal-vs-N1 |
3.82449999447587E-08 |
| N0-vs-N1 |
6.964300E-02 |
|
|
